CTS Spotlight at 2018 AABB Annual Meeting
Sunday, October 14, 2018 at 1:30 PM: Scientific Oral Abstract Plenary Session (BBC57) Multicenter Clinical Evaluation of a Babesia Transcription-Mediated Amplification Assay on a Fully Automated System Phillip C. Williamson, Ph.D.
Monday, October 15, 2018 at 2:30PM: (BBC2-MN3-24) Recently Acquired Hepatitis C Infections in US Blood Donors: Genotype and Geographic Distribution of NAT Yield Blood Donations across the Continental US Valerie Winkelman and Phillip C. Williamson, Ph.D.
Tuesday, October 16, 2018 at 11:45AM a: (PHP2 - TU3-23) Characteristics of HIV Infections, Including Genotypes and Drug Resistance Mutations, in Blood Donors in the US Phillip C. Williamson, Ph.D.
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
On September 23, 2019, the new CTS Laboratory Information System successfully implemented in Da...
CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The ...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...